Interleukin-6 as a therapeutic target in ovarian clear cell carcinoma

Led by Professor Iain McNeish, this project looked at developing new treatments for ovarian clear cell carcinoma, a rare subtype of ovarian cancer.

There are several different types of ovarian cancer, and distinct approaches are required to treat each type successfully. Clear cell carcinoma can be particularly aggressive. However, there are no existing treatments that target this type of ovarian cancer, which responds very poorly to conventional chemotherapy.

Recent research in the laboratory shows that a molecule called interleukin-6 (IL-6) may be critical in the development of ovarian clear cell carcinoma. The team evaluated the effectiveness of drugs that block IL-6, which could then be used as potential treatments for clear cell ovarian cancer.

The overall aims of the project were to explore whether targeting IL-6 may be promising in the treatment of ovarian clear cell carcinoma. This project has now completed and we hope to be able to report its results soon.